US FDA’s Novel Neuroscience Approvals Plunged In 2025, But 2026 Candidates Are Coming

 
• By Bridget Silverman
  
perspectives 2026
Neuroscience failed to make the impact on 2025 approvals that the pipeline promised. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pink Sheet Perspectives

More from Pink Sheet